CN106661113A - Hiv抗体治疗作为治疗替代 - Google Patents

Hiv抗体治疗作为治疗替代 Download PDF

Info

Publication number
CN106661113A
CN106661113A CN201580044550.6A CN201580044550A CN106661113A CN 106661113 A CN106661113 A CN 106661113A CN 201580044550 A CN201580044550 A CN 201580044550A CN 106661113 A CN106661113 A CN 106661113A
Authority
CN
China
Prior art keywords
hiv
pro
experimenter
treatment
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580044550.6A
Other languages
English (en)
Chinese (zh)
Inventor
R·T·斯库雷
N·Z·珀尔哈桑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cimetropium Dane Ltd By Share Ltd
Cytodyn Inc
Original Assignee
Cimetropium Dane Ltd By Share Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cimetropium Dane Ltd By Share Ltd filed Critical Cimetropium Dane Ltd By Share Ltd
Publication of CN106661113A publication Critical patent/CN106661113A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580044550.6A 2014-08-20 2015-08-20 Hiv抗体治疗作为治疗替代 Pending CN106661113A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462039620P 2014-08-20 2014-08-20
US62/039,620 2014-08-20
US201562192941P 2015-07-15 2015-07-15
US62/192,941 2015-07-15
PCT/US2015/046160 WO2016029049A1 (en) 2014-08-20 2015-08-20 Hiv antibody therapy as treatment substitute

Publications (1)

Publication Number Publication Date
CN106661113A true CN106661113A (zh) 2017-05-10

Family

ID=55351264

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580044550.6A Pending CN106661113A (zh) 2014-08-20 2015-08-20 Hiv抗体治疗作为治疗替代

Country Status (11)

Country Link
US (2) US10562969B2 (https=)
EP (2) EP3904390A1 (https=)
JP (2) JP6767367B2 (https=)
KR (1) KR20170042706A (https=)
CN (1) CN106661113A (https=)
AU (2) AU2015305401A1 (https=)
BR (1) BR112017003252A2 (https=)
CA (1) CA2957817A1 (https=)
ES (1) ES2880950T3 (https=)
MX (1) MX2017002093A (https=)
WO (1) WO2016029049A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024008177A1 (en) * 2022-07-08 2024-01-11 Nanjing Curegene Technology Co., Ltd. Engineered cells and uses thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11584797B2 (en) 2015-06-23 2023-02-21 Cytodyn Inc. Inhibition of CCL5 ligand binding to CCR5 receptor and alteration of CCR5/CCL5 axis signaling in inflammation, cancer, autoimmune, and other conditions
US20190085086A1 (en) * 2017-09-18 2019-03-21 Cytodyn Inc. Screening methods for identifying and treating hiv-1 infected patient sub-populations suitable for long term anti-ccr5 agent therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008134076A1 (en) * 2007-04-30 2008-11-06 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
CN101495145A (zh) * 2005-07-22 2009-07-29 原基因药物有限公司 用于减少受hiv-1感染的患者中病毒负荷的方法
US20130216526A1 (en) * 2008-04-30 2013-08-22 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1 infected patients

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
AU2004251228B2 (en) 2003-05-16 2008-04-24 University Of Maryland Biotechnology Institute Compositions for down-regulation of CCR5 expression and methods of use therefor
US9956165B2 (en) 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101495145A (zh) * 2005-07-22 2009-07-29 原基因药物有限公司 用于减少受hiv-1感染的患者中病毒负荷的方法
WO2008134076A1 (en) * 2007-04-30 2008-11-06 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
US20130216526A1 (en) * 2008-04-30 2013-08-22 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1 infected patients

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JEFFREY M. JACOBSON ET AL.: "Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody", 《J INFECT DIS.》 *
JEFFREY M. JACOBSON ET AL.: "Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 *
KUSH DHODY ET AL.: "PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection", 《HIV CLINICAL TRIALS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024008177A1 (en) * 2022-07-08 2024-01-11 Nanjing Curegene Technology Co., Ltd. Engineered cells and uses thereof

Also Published As

Publication number Publication date
EP3904390A1 (en) 2021-11-03
KR20170042706A (ko) 2017-04-19
MX2017002093A (es) 2017-05-25
AU2015305401A1 (en) 2017-03-02
EP3183270A1 (en) 2017-06-28
JP7035143B2 (ja) 2022-03-14
US20200385475A1 (en) 2020-12-10
JP2021004249A (ja) 2021-01-14
BR112017003252A2 (pt) 2017-11-28
CA2957817A1 (en) 2016-02-25
WO2016029049A1 (en) 2016-02-25
EP3183270A4 (en) 2018-01-17
EP3183270B1 (en) 2021-04-28
JP2017527613A (ja) 2017-09-21
AU2021202132A1 (en) 2021-05-06
US10562969B2 (en) 2020-02-18
US20170335002A1 (en) 2017-11-23
JP6767367B2 (ja) 2020-10-14
ES2880950T3 (es) 2021-11-26

Similar Documents

Publication Publication Date Title
Sacco et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
Tsuji et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti‐infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP)
McArthur et al. Human immunodeficiency virus‐associated neurocognitive disorders: Mind the gap
Fulcher et al. Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection
Rafatpanah et al. The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran
M Amedee et al. Chronic alcohol abuse and HIV disease progression: studies with the non-human primate model
Choi Convalescent plasma therapy for coronavirus disease 2019
Bellio et al. Proof-of-concept trial of an amniotic fluid-derived extracellular vesicle biologic for treating high risk patients with mild-to-moderate acute COVID-19 infection
Arrigo et al. Management of paediatric IBD after the peak of COVID-19 pandemic in Italy: A position paper on behalf of the SIGENP IBD working group
JP7035143B2 (ja) 代替処置としてのｈｉｖ抗体療法
Zhang et al. Efficacy and safety of tripterygium wilfordii Hook F plus TNF inhibitor for active rheumatoid arthritis: A multicentre, randomized, double-blind, triple-dummy controlled trial
Li et al. Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection
Touzard Romo et al. Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175)
Ma et al. Therapeutic antibodies under development for SARS‐CoV‐2
Hadia et al. A Comprehensive Review of the Safety and Efficacy of Lenacapavir in the Treatment of Human Immunodeficiency Virus.
HK40063361A (en) Hiv antibody therapy as treatment substitute
Zhao et al. Monoclonal CCR5 antibody: a promising therapy for HIV
Liang et al. Efficacy and safety of Opinercept tumor necrosis factor inhibitor therapy for Drug-Refractory rheumatoid arthritis: a randomized clinical trial
Traore et al. Impact of low dose naltrexone (LDN) on antiretroviral therapy (ART) treated HIV+ adults in Mali: a single blind randomized clinical trial
Plummer et al. COVID-19 Vaccines for HIV-Infected Patients. Viruses 2021, 13, 1890
Antar et al. CROI 2025: Acute and Postacute COVID-19
AbdelMassih et al. Non-Multisystem Inflammatory Syndrome in Children—Postacute Sequelae of Paediatric COVID-19: Autoimmune or Autoinflammatory? A Systematic Review of the Reported Cases. Rheumato 2023, 3, 132–168
Declerck et al. Clinical characteristics and treatments of imported loiasis patients with microfilaraemia diagnosed in France, 2000-2022
Peterson The Efficacy of Tocilizumab as a Therapeutic Treatment for SARS-CoV-2 Infections: An Integrative Literature Review
Hespen Guillain-Barre Syndrome: A Review of Current Diagnostic Tools, Treatments, and Research

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination